Ashwagandha (Withania somnifera) is an herbal supplement sold for stress, sleep, and general wellness. It is not a controlled substance, and it is not one of the analytes that a standard workplace or clinical drug test panel is built to find. People who take it still ask the question because a positive screen is stressful, and because supplement labels rarely explain what a drug test actually measures. This article explains the difference between a screening immunoassay and a confirmation test, names the drug classes ashwagandha is not part of, and walks through what the published literature does and does not say about cross reactivity.
What a Screening Test Actually Measures
Most drug test cups, dip cards, and oral fluid devices use immunoassay chemistry. An immunoassay uses antibodies that bind to a target drug or its metabolite, and a reaction at or above a set cutoff produces a presumptive positive result. These screens are fast and inexpensive, but they are not identifying a molecule by its exact structure. They are reacting to anything that resembles the target closely enough to bind the antibody. That is why screening results are considered presumptive, not final.
Any presumptive positive that matters for an employment, legal, or clinical decision should go to confirmation testing, typically gas chromatography mass spectrometry (GC/MS) or liquid chromatography mass spectrometry (LC/MS). Confirmation testing identifies the specific compound and its concentration, and it is what separates a true positive from a screen that reacted to something unrelated. A medical review officer (MRO) reviews confirmed positive results and compares them against verified prescriptions before an employer ever sees a final determination, under the structure set out in 49 CFR Part 40.
Which Panel Classes Ashwagandha Is Not Part Of
Standard 5, 10, and 12 panel immunoassays are built to detect specific drug classes: amphetamines and methamphetamine, opiates, cocaine metabolite, THC metabolite, phencyclidine (PCP), benzodiazepines, barbiturates, methadone, propoxyphene, methaqualone, and in some panels oxycodone or synthetic opioids as separate strips. Ashwagandha's active compounds, a group of steroidal lactones called withanolides, are not chemically related to any of those target classes. The National Center for Complementary and Integrative Health (NCCIH), part of NIH, describes ashwagandha as an herbal supplement studied for stress, sleep, and testosterone related outcomes, with no connection to the drug classes workplace panels are designed to catch.
Is There Any Documented Cross Reactivity?
There is no published cross reactivity evidence linking ashwagandha or withanolides to a false positive on a standard immunoassay panel. The NCCIH safety summary for ashwagandha does not list drug test interference among its known effects or cautions, and none of the major cross reactivity literature on amphetamine, opiate, benzodiazepine, or THC immunoassays identifies withanolide compounds as a known interferent. That is different from saying no cross reactivity could ever be reported in the future. It means that, based on the evidence available now, ashwagandha is not a documented cause of a false positive, and any positive result in someone taking only ashwagandha should be treated as unexplained and sent to confirmation testing rather than attributed to the supplement.
This is also the point where program design matters. A screening cup or dip card gives a quick presumptive read so a clinic or employer can triage results. A confirmed positive that leads to an actual decision should always clear GC/MS or LC/MS confirmation and MRO review first, regardless of what the person reports taking.
The Real Risk With Supplements Is the Product, Not the Herb
Dietary supplements are regulated differently than prescription drugs in the United States. The FDA does not review a supplement for safety or effectiveness before it reaches a store shelf the way it reviews a new drug application. The agency's own consumer guidance on using dietary supplements notes ongoing recalls, warnings, and health fraud actions tied to contamination and undeclared ingredients in supplement products. That is the real exposure for anyone taking ashwagandha or any other herbal product before a drug test. It is not that ashwagandha itself reacts with a panel. It is that a mislabeled or adulterated bottle could contain an undeclared stimulant, a steroid, or another active ingredient that was never on the label, and that ingredient, not the ashwagandha, is what could show up.
This is also why a supplement cannot be documented to an MRO the way a prescription can. Under the MRO process described in 49 CFR Part 40, a verified prescription with a pharmacy record and a prescriber can explain a confirmed positive for certain drug classes. A supplement bottle has no NDC number, no pharmacy fill record, and no prescriber to call. If a confirmed positive for a regulated drug class ever did occur in someone taking a supplement, the supplement itself generally cannot excuse that result, because there is nothing to verify. The SAMHSA workplace resources page is the government starting point for how MRO review and employer drug testing programs are supposed to work.
Ashwagandha, the Liver, and a Separate Safety Question
Apart from drug testing, there is a documented safety question about ashwagandha and the liver. NIH's LiverTox database, a clinical reference on drug and herbal product induced liver injury, maintains an entry on ashwagandha cataloging published case reports where liver injury was temporally linked to ashwagandha use. NCCIH's own safety summary echoes this, noting that while ashwagandha appears to be reasonably well tolerated short term, a number of case reports have linked liver injury to ashwagandha products, and that long term safety data is limited. This has nothing to do with drug test panels. It is a separate clinical question, and anyone with concerns about supplement use and liver health should raise it with a physician rather than look for an answer in a drug test result.
Common Supplements and What Panels Actually Know About Them
| Supplement | Controlled substance | On a standard 5/10/12 panel | Documented cross reactivity | Primary documented risk |
|---|---|---|---|---|
| Ashwagandha (Withania somnifera) | No | No | None published | Rare case reports of liver injury (LiverTox) |
| Kava (Piper methysticum) | No | No | None published on standard panels | Case reports of liver injury |
| Kratom (Mitragyna speciosa) | Not federally scheduled; some states and cities restrict it | No, standard panels do not include it; a dedicated KRA (mitragynine) strip or send out lab confirmation is required | Not applicable to routine opiate panels; compounds such as mitragynine and 7-hydroxymitragynine are not targeted analytes on rapid panels | Products marketed as kratom have been tied to poison control calls and overdose reports, often with undisclosed additives |
| CBD (cannabidiol) | Hemp derived CBD at or below 0.3 percent THC is not federally scheduled | The THC panel targets a THC metabolite, not CBD itself | Trace THC present in some CBD products has, in isolated cases, been enough to trigger a THC screen | Inconsistent labeling; actual THC content can differ from what the label states |
| Melatonin | No | No | None published | Supplement content has been found to vary from label claims in independent testing |
| St. John's wort (Hypericum perforatum) | No | No | None published on standard panels | Known to reduce the effectiveness of many prescription medications through drug interactions, not a testing issue |
Every row above carries the same caveat as ashwagandha. The customer should always confirm with the testing lab which specific analytes a given panel or send out test covers, especially for kratom, where rapid panels will not detect mitragynine or 7-hydroxymitragynine unless a dedicated strip or lab confirmation is ordered.
What an Employer or Clinic Should Do With a Disclosed Supplement
A sensible collection policy lets a donor list current medications and supplements on the chain of custody form before the test, not after a result comes back. That disclosure does not change how the panel is run, and it does not excuse a confirmed positive the way a verified prescription can under MRO review. What it does is give the MRO useful context if a result ever needs a closer look, and it gives the employer a documented, consistent process instead of an ad hoc conversation after the fact. Programs that want a refresher on how panel selection and confirmation testing fit together can review how to evaluate another herbal supplement like kava against standard panels or how a CBD product's trace THC content can occasionally affect a THC screen, both of which follow the same screen first, confirm second structure described here.
Clinics and employers building or restocking a testing program can find cups, dip cards, and oral fluid devices through American Screening Corporation's drug test cup collection. Organizations that purchase in volume can also check the wholesale portal for case level ordering.
Frequently asked questions
Does ashwagandha show up on a 5 panel or 10 panel drug test?
No. Standard immunoassay panels screen for specific drug classes such as amphetamines, opiates, THC, cocaine, and PCP. Ashwagandha is an herbal supplement, not a controlled substance, and it is not one of the analytes those panels target.
Can ashwagandha cause a false positive on a drug test?
There is no published evidence of ashwagandha or its withanolide compounds cross reacting with standard immunoassay screens, according to NIH's National Center for Complementary and Integrative Health. A positive screen in someone using ashwagandha should go to confirmation testing and medical review officer evaluation rather than be attributed to the supplement.
Is ashwagandha a controlled substance?
No. Ashwagandha (Withania somnifera) is not scheduled under the Controlled Substances Act and is sold as a dietary supplement in the United States.
Can a supplement like ashwagandha be documented to a medical review officer the way a prescription can?
Not in the same way. A medical review officer reviews confirmed positive results against verified prescriptions under the process set out in 49 CFR Part 40. A supplement has no pharmacy fill record or prescriber behind it, so it generally cannot explain away a confirmed positive for a regulated drug class.
What is the real risk of taking ashwagandha supplements?
Dietary supplements are not reviewed by the FDA for safety and effectiveness before they reach the market the way prescription drugs are, so contamination or undeclared ingredients are possible. Ashwagandha has also been linked to rare case reports of liver injury cataloged in NIH's LiverTox database, which is a clinical safety question separate from drug testing.
Does a positive THC or opiate screen while taking ashwagandha mean the supplement caused it?
Not based on current evidence. Because ashwagandha is not a documented cross reactant on standard panels, a positive screen is more likely explained by another substance, an undeclared ingredient in the product, or actual use of the screened drug. Confirmation testing with GC/MS or LC/MS resolves the question.
This article is general information about drug test science and supplement regulation, not medical or legal advice. Anyone with questions about a specific test result, medication, or supplement should talk to a medical review officer or a physician.